

Clinical research on emerging medical technologies in Japan: Implementation, evaluation, and evidence generation

Takashi Karako*

National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.

Abstract: Two articles in this issue report on early Japanese clinical implementation of histotripsy for liver tumors and pressurized intraperitoneal aerosol chemotherapy for peritoneal metastases. Together, these reports illustrate how procedure-dependent technologies enter a new healthcare system and how their early clinical use can be evaluated. The clinical value of such interventions depends on more than device access or operator skill. It requires patient selection, appraisal of evidence from abroad, regulatory and ethical review, simulations, multidisciplinary workflow, safety governance, and outcome assessment that separates technical completion from patient benefit. Japan has the clinical expertise and institutional structures to carefully introduce selected technologies, but first-in-country use should serve as a starting point for local evidence generation rather than an endpoint. A practical pathway is proposed in which initial clinical introduction is embedded within protocolized evaluation and followed by assessment of reproducibility and comparison with established treatment options.

Keywords: first-in-country use, multidisciplinary workflow, patient selection, regulatory science, complex interventions

1. A shared problem in early clinical introduction

In this issue of *Global Health & Medicine*, Ishizawa and colleagues report on the first clinical implementation of histotripsy for liver tumors in Japan, and Takeuchi and colleagues report on the first implementation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases in Japan (1,2). The two technologies differ in target disease, physical principle, equipment, and therapeutic intent. Their shared importance lies elsewhere. Together, the two reports illustrate that safe and evaluable clinical introduction depends not only on the technology itself but also on local systems for training, governance, workflow, and evaluation.

Histotripsy has advanced through pivotal and early post-approval use that substantiates its feasibility and that sheds light on patient selection, while safety and local control continue to require careful follow-up (3,4). PIPAC has similarly been supported by rationale papers, technical guidance, and early-phase clinical data in patients with peritoneal metastases (5-7). Such evidence is necessary for introduction, but it is not sufficient for domestic dissemination. Local implementation requires answering a separate research question: can the

technology be used safely, reproducibly, and ethically within the Japanese clinical environment?

2. Protocolized first use, not demonstration alone

In both reports, treatment of the first patient was preceded by a structured process that included protocol development, training or observation, institutional review, and team preparation. In the PIPAC report, the implementation process was particularly explicit: international training, animal experiments, operating-room simulations, pharmacy and injector workflows, remote anesthesia management, closed evacuation, and a staged safety checklist were established before clinical use (2). The histotripsy report also emphasizes an approved clinical research protocol, operator training, simulations with operating-room staff, and early safety surveillance (1).

This distinction is important. A first-in-country procedure has limited scientific value if it is presented only as a technical achievement. Clear reporting of preparations, eligibility criteria, safety measures, outcome definitions, and limitations strengthens the value of these early clinical experiences and helps other institutions assess whether and how the pathway can be




Figure 1. Clinical research pathway for emerging medical technologies in Japan. The pathway begins with a defined clinical need and patient selection, followed by appraisal of domestic evidence and evidence from overseas and assessment of local readiness. Early clinical use should follow a predefined protocol under appropriate ethical and regulatory oversight, with outcome assessment that separates technical completion from patient-relevant benefit. Broader clinical positioning should depend on reproducibility, safety, patient selection, comparative value, and feasibility in routine practice. Cross-cutting requirements include ethical and regulatory governance, multidisciplinary readiness, safety and quality workflow, and patient-relevant outcomes.

replicated.

3. Evaluation after technical success

Procedure-dependent technologies can be viewed as complex clinical interventions because their performance depends not only on the device or procedure itself but also on operator expertise, team coordination, and the clinical setting in which they are delivered. Reporting guidance such as the Template for Intervention Description and Replication (TIDieR) and broader methodological work on complex interventions are therefore relevant (8,9). For this reason, early reports should distinguish technical completion, short-term safety, biological effects, and patient-relevant benefit.

For histotripsy, early endpoints may include target visualization, treatment-zone coverage, perioperative adverse events, and short-term imaging. Later evaluation should address local tumor control, recurrence, liver function, quality of life, retreatment, and comparison with established options such as resection, thermal ablation, and radiotherapy. For PIPAC, early feasibility includes access, aerosolization, containment, occupational safety workflow, symptom burden, and recovery. Subsequent assessment should examine repeated administration, response within the peritoneal cavity, systemic treatment sequencing, quality of life, and selection relative to cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and systemic therapy.

4. A practical pathway for Japan

Japan is a suitable setting for evaluable introduction of select emerging technologies because it combines advanced clinical expertise with formal structures for clinical research oversight. The Clinical Research Act and related review systems provide a framework for enhancing

the reliability and transparency of clinical research conducted under applicable regulatory oversight in Japan (10). This framework can be used not only to control risk but also to generate evidence that is relevant to Japanese practice. Japan's universal health insurance system also gives local evidence generation particular importance. Once sufficient evidence has been established and appropriate reimbursement is obtained, a new technology may become accessible within a nationally regulated framework of care.

A practical pathway is summarized in Figure 1. It begins with a defined clinical need and patient selection, followed by appraisal of domestic evidence and evidence from abroad. Local readiness should then be assessed, including training, staffing, facilities, emergency plans, pharmacy or engineering requirements, data capture, and conflict-of-interest management. Protocol-based first use should be followed by outcome assessment that separates technical success from clinical benefit. Further evidence on reproducibility, safety, patient selection, and comparative clinical value is needed to inform decisions about broader dissemination. These considerations apply across all stages of implementation and evaluation.

5. Conclusion

The two reports in this issue should not be viewed simply as the arrival of two new technologies in Japan. They illustrate a broader requirement for contemporary clinical research: innovations must be introduced through pathways that are prepared, transparent, reproducible, and evaluable. First-in-country use is meaningful when it creates the conditions for generating evidence from local practice. The next task is therefore not rapid diffusion alone but disciplined evaluation that can determine when, for whom, and in relation to which established treatments these technologies should become part of routine care.

Funding: None.

Conflict of Interest: The author has no conflicts of interest to disclose.

References

- Ishizawa T, Kinoshita M, Nishimura S, Shinkawa H, Sada R, Tateishi C, Tanaka D, Motomura H, Mori T, Yamamoto A, Uchida-Kobayashi S. First clinical implementation of histotripsy for liver tumors in Japan. *Glob Health Med.* 2026; 8:379-383.
- Takeuchi H, Gohda Y, Kitayama J, Kato T, Hieda Y, Shimano H, Kudo H, Kokudo N. First reported clinical implementation of pressurized intraperitoneal aerosol chemotherapy in Japan: Program development and 30-day outcomes in two patients. *Glob Health Med.* 2026; 8:371-378.
- Ziemlewicz TJ, Critchfield JJ, Mendiratta-Lala M, *et al.* The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors: One-year update of clinical outcomes. *Ann Surg.* 2025; 282:908-916.
- Wehrle CJ, Burns K, Ong E, *et al.* The first international experience with histotripsy: A safety analysis of 230 cases. *J Gastrointest Surg.* 2025; 29:102000.
- Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications. *Lancet Oncol.* 2019; 20:e368-e377.
- Hübner M, Alyami M, Villeneuve L, Cortés-Guiral D, Nowacki M, So J, Sgarbura O; ISSPP PIPAC study group. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. *Eur J Surg Oncol.* 2022; 48:789-794.
- Raoof M, Whelan RL, Sullivan KM, *et al.* Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA. *Ann Surg Oncol.* 2023; 30:7814-7824.
- Hoffmann TC, Glasziou PP, Boutron I, *et al.* Better reporting of interventions: Template for Intervention Description and Replication (TIDieR) checklist and guide. *BMJ.* 2014; 348:g1687.
- Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: Update of Medical Research Council guidance. *BMJ.* 2021; 374:n2061.
- Ministry of Health, Labour and Welfare. Clinical Research Act. <https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000163417.html> (accessed September 28, 2026). (in Japanese)

Received October 2, 2026; Accepted October 12, 2026.

Released online in J-STAGE as advance publication October 14, 2026.

**Address correspondence to:*

Takashi Karako, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
E-mail: politang-ky@umin.ac.jp